The scourge of Cancer has ravaged the society and the resultant damage is often too scathing and excruciating to bear. Consequently, several attempts have been put in place in order to counteract the colossal damage posed by cancer to the human species. One Company that has been the vanguard in the war against cancer is Seattle Genetics. This is an American-based company that was founded by Dr Clay Siegall in 1998, and it envisages combatting the cancer pandemic by developing a series of targeted therapy drugs.
Dr Clay Siegall has always dedicated his entire medical career and channelled all his efforts in putting up a strong fight against cancer. In an exclusive interview with Inspirery, he explicated a myriad of issues regarding Seattle Genetics, its missions and visions. First of all, Clay Siegall began by narrating how he began the business, the inspiration that kept him going, and how he got his first customer.
He further shed some light on the marketing strategy that he uses other than referrals. He reiterated that negotiations have played an indispensable role in ensuring that Seattle Genetics generates and maintains new business. He also pointed out that work habits play a salient role in ensuring the success of any entity; passion and focus are the major driving forces towards success whereas IQ and academic credentials are ancillary.
Being a scientist by training, Clay Siegall is the President, Chief Executive Officer as well as the Chairman of the Board of Management of Seattle Genetics. He also has a vast experience that spans for over 25 years, having worked in leadership positions for corporations such as Bristol-Myers Squibb Pharmaceutical Research Institute, Alder Biopharmaceuticals, and the National Cancer Institute. Under his splendid leadership, the efforts of combatting cancer are commendably looking up. Foremost, the company has been successful in developing Antibody-Drug Conjugates which are the touchstone for the treatment of cancer.
Furthermore, the superb leadership skills exuded by Clay Siegall have enabled the company to procure several strategic licences regarding Antibody-Drugs Conjugates that are aimed at amassing more resources for the company. As a matter of fact, the company has garnered up to $300 million from these transactions. Some of the corporations with which they have entered into strategic licences include Genentech and GlaxoSmithKline.
The fight against cancer has always been a daunting odyssey and many cancer patients have had their hopes of getting well crumbled down. However, the progress made by Seattle Genetics in terms of developing the ADC’s gives them a whiff of hope and also enables them to see light at the end of the tunnel in this respect.